Invention Grant
- Patent Title: Histone demethylase inhibitors
-
Application No.: US15891927Application Date: 2018-02-08
-
Publication No.: US10208039B2Publication Date: 2019-02-19
- Inventor: Amogh Boloor , Toufike Kanouni , Jeffrey Alan Stafford , James Marvin Veal , Michael Brennan Wallace
- Applicant: CELGENE QUANTICEL RESEARCH, INC.
- Applicant Address: US CA San Diego
- Assignee: Celgene Quanticel Research, Inc.
- Current Assignee: Celgene Quanticel Research, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Wiley Rein LLP
- Main IPC: C07D239/70
- IPC: C07D239/70 ; C07D471/04 ; A61K31/505 ; A61K31/395 ; C07D227/00 ; A61K31/519 ; A61K31/404 ; C07D209/04 ; C07D239/00

Abstract:
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, and the like.
Public/Granted literature
- US20180162857A1 HISTONE DEMETHYLASE INHIBITORS Public/Granted day:2018-06-14
Information query